EXEL - Exelixis says lung cancer therapy failed in Phase 3 trial
- Oncology-focused biotech Exelixis, Inc. ( NASDAQ: EXEL ) has announced that its tyrosine kinase inhibitor cabozantinib in combination with Roche’s ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) anti-PD-1/PD-L1 therapy atezolizumab did not meet the primary goal of overall survival in a Phase 3 trial for lung cancer.
- The CONTACT-01 study tested cabozantinib (Cabometyx) with atezolizumab (Tecentriq) against chemotherapy docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) as a second-line option.
- The open-label trial involved 366 NSCLC patients without actionable mutations whose disease progressed despite receiving an immune checkpoint inhibitor and platinum-containing chemotherapy.
- According to the final analysis, CONTACT-01 did not meet the main goal of overall survival. The safety profile of the cabozantinib/ atezolizumab combo was consistent with those of each agent, and the trial indicated no new safety signals.
- The trial was sponsored by Roche ( OTCQX:RHHBY ) and co-funded by Exelixis ( EXEL ), Ipsen ( OTCPK:IPSEF ) ( OTCPK:IPSEY ), and Takeda Pharmaceutical ( TAK ).
- Read: Seeking Alpha contributor Bret Jensen called Exelixis ( EXEL ) an “unloved value stock” and explains how to trade its shares.
For further details see:
Exelixis says lung cancer therapy failed in Phase 3 trial